Facebook Facebook Facebook Facebook
24
Jun 15

Exciting new data on HT-100!

Recently, Akashi Rx published data from their Phase 1b/2a trial of HT-100.  HT-100, also known as halofuginone, is a powerful anti-fibrotic/anti-inflammatory that will help ALL boys with Duchenne, regardless of mutation.  The Little Hercules Foundation is proud to be a financial supporter of this promising therapy.  Read the press release here!

Sign up for Updates

No spam. Just periodic updates on what we are doing and how you can help.

Close
loading...